Paul J. Hastings
CEO & DirectorMr. Paul J. Hastings has been Independent Director of Azora Therapeutics, Inc. since November 3, 2026. He is Chairman of Specific Biologics Inc. from June 2025. Mr. Hastings had been President of Nkarta, Inc. since February 2018 until July 2024 and serves as its Chief Executive Officer as well as Director since February 2018. He is Independent Director of enGene Therapeutics Inc. (formerly known as enGene Holdings Inc.) from May 15, 2024. Mr. Hastings served as Chair of the Board of Pacira BioSciences, Inc. (formerly known as Pacira Pharmaceuticals, Inc.) since January 02, 2024 until January 2025 and served as its Lead Director since June 2013. Mr. Hastings has years of biotech and pharmaceutical experience. Mr. Hastings served as the Chief Executive Officer and President of OncoMed Pharmaceuticals, Inc. from January 2006 to January 1, 2018. Mr. Hastings joined OncoMed in 2006. He served as the Chief Executive Officer, President and Director of Novelion Therapeutics Inc. from February 2002 to September 2006. He served as Business Advisor at Valocor Therapeutics, Inc. From 1994 to 1998, Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President, Genzyme Therapeutics. He served as Chief Executive Officer, President and Director of Axys Pharmaceuticals, Inc from 2000 to 2002. He served as the Chief Executive Officer, President and Director at LXR Biotechnology Inc. since August 1998 until 1999. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals. Mr. Hastings served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc. and held a series of marketing and sales management positions with Hoffmann-La Roche. He had been Chairman and as a Member of the Board of Directors of Proteon Therapeutics Inc. since October 20, 2016 until 2020. He served as Chairman of OncoMed Pharmaceuticals, Inc. from August 2013 to January 1, 2018. He served as Chairman of Onyx Therapeutics, Inc. Mr. Hastings served as Chairman of Proteolix (sold to Onyx Pharmaceuticals in 2010) From September 2008 to November 2009. He had been a Director of ViaCyte, Inc. since July 24, 2019 until November 2022. He was a Director of OncoMed Pharmaceuticals, Inc. since January 2006 until January 1, 2018. He serves as Vice Chairman and Director of Biotechnology Innovation Organization. He serves as a Director of Arriva Pharmaceuticals, Inc. He served as Director at Protara Therapeutics, Inc. He served as a Director of Chiron, Corp. He served as a Director of Relypsa, Inc. since October 2012 until September 1, 2016. He served as a Director of Cerimon Pharmaceuticals, Inc. Prior to joining OncoMed, Mr. Hastings was President, Chief Executive Officer and Director of QLT, Inc. from February 2002 to September 2006. He served as a Director of ViaCell, Inc from November 2000 to November 2007 which is a publicly traded biotechnology company that was sold to Perkin Elmer in 2007. He served as the Chairman of Bay Area Bioscience Association. He serves as a Director of California Life Sciences Association since April 2010. Mr. Hastings holds a Bachelor of Science Degree in Pharmacy from the University of Rhode Island.
Positions
- Company NameNkarta, Inc.Stock CodeNKTXPositionCEO & DirectorColleagues
- Company NameAzora Therapeutics, Inc.Stock CodeAZRPositionIndependent Director
